Project Grant K08CA297136
Award Date 9/19/25
Completion Date 8/31/30
Dollars Obligated $281K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Pennsylvania, USA
Similar Awards
- This federal Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) provides $621,156 to The Trustees of the University of Pennsylvania to conduct research aimed at identifying novel regulators of endoplasmic reticulum (ER) homeostasis in malignant plasma cells, with the goal of developing new therapies to target and kill multiple myeloma cells. The 5-year project, starting on January 1, 2025, will leverage experimental systems including a...
- The University of Miami received a $674,440 Project Grant award from the National Cancer Institute (NCI) under the Cancer Biology Research federal grant program (CFDA 93.396). The 5-year project, which began on February 3, 2025, aims to comprehensively define the genomic events and immune microenvironment that differentiate benign from malignant multiple myeloma precursor conditions. Using cutting-edge single-cell whole genome sequencing and RNA analysis, the research seeks to identify key...
- This Project Grant award, valued at $173,500 and issued by the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research), supports research to investigate the effects of CXCR1/2 inhibition on the immune microenvironment of patients with multiple myeloma. The awardee, Health Research, Inc., a not-for-profit research organization in Buffalo, NY, will use single-cell transcriptomics to characterize the phenotype and transcriptional changes in myeloid cells in the bone marrow and...
- This Project Grant award from the National Cancer Institute (CFDA 93.398 Cancer Research Manpower) provides $100,760 to the Sloan-Kettering Institute for Cancer Research in New York, NY to engineer biomaterials that modulate the tumor immune microenvironment for the treatment of multiple myeloma. The research aims to develop a novel RNA interference (RNAi) therapy that inhibits the expression of cyclophilin A and E-selectin, critical factors for multiple myeloma cell homing, progression, and...
- This federal Project Grant award of $620,521, provided by the National Cancer Institute (CFDA 93.394 - Cancer Detection and Diagnosis Research), supports an integrated mathematical modeling approach to define how the aging bone ecosystem drives multiple myeloma evolution and treatment response. The key products and services to be delivered under this 5-year award, which commenced on January 1, 2025, include: Developing a novel hybrid cellular automata mathematical model to describe the...
- This Project Grant award of $196,029 from the National Cancer Institute (NCI) under the Cancer Research Manpower federal grant program (CFDA 93.398) supports research at the University of Massachusetts Medical School (UMass Medical) to investigate immune evasion mechanisms in cancers with mutant isocitrate dehydrogenase 1 (mIDH1). The project aims to decipher the basis of mIDH1-mediated immune suppression, focusing on two key mechanisms: 1) the tumor cell-intrinsic pathway that impairs...
- This $194,688 Project Grant award from the National Cancer Institute (CFDA 93.398 Cancer Research Manpower program) supports research by Indiana University Indianapolis to investigate the role of the GATA2 gene in acute myeloid leukemia (AML) and the MonoMAC syndrome. The key objectives are to: 1) Define the genes regulated by the normal GATA2 protein and how their expression is altered by AML- and MonoMAC-associated GATA2 mutations, using a novel mouse model and overexpression studies in...
- This federal Project Grant award from the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420) provides $713,250 over 3 years to the Trustees of Indiana University (doing business as Indiana University) to conduct research targeting the CENPF-CENPE axis for the prevention and treatment of NF1-associated malignant peripheral nerve sheath tumors. The research aims to develop new approaches for addressing this condition, which impacts military service...
- This federal Project Grant award of $344,111 from the National Cancer Institute (CFDA 93.396 - Cancer Biology Research) supports research by Loyola University of Chicago to investigate "Targeting Panoptotic Pathways for Myelodysplastic Syndromes Treatment". The research aims to advance the understanding of the fundamental biological mechanisms underlying myelodysplastic syndromes (MDS), a group of bone marrow failure diseases. Specifically, the project will explore the role of...
- This federal Project Grant award of $623,120.00, provided by the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research), supports research aimed at developing new chemical "degrader" tools to target critical chromatin regulators that drive the aberrant gene expression patterns observed in multiple myeloma. The award to the General Hospital Corporation, doing business as Massachusetts General Hospital, will fund two specific aims: 1) using the degrader tools to assess the...